循环长链非编码RNA作为心血管疾病生物标志物的研究进展
Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases.
作者信息
Cao Mingyi, Luo Huishan, Li Danning, Wang Shengjie, Xuan Lina, Sun Lihua
机构信息
Department of Pharmacology, Harbin Medical University (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
Department of Pharmacology, Harbin Medical University (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.
出版信息
Int J Cardiol. 2022 Apr 15;353:109-117. doi: 10.1016/j.ijcard.2022.01.070. Epub 2022 Feb 8.
Cardiovascular diseases (CVD) such as myocardial ischemia, myocardial infarction, heart failure, atherosclerosis, hypertension, arrhythmia, and their complications diseases are associated with increased morbidity and mortality, it is necessary to develop new diagnostic markers for CVD. LncRNAs have become a new class of biomarkers in CVD with good development prospects. Numerous studies have confirmed lncRNAs feasibility as diagnostic, prognostic and predictive tools for different types of CVD. In this review, we summarized the available knowledge regarding the clinical application value and pathophysiological mechanism of circulating lncRNA as potential biomarkers of cardiovascular disease. We reviewed the scope of application and changes of circulating lncRNAs such as ZFAS1, CDR1AS, CHAST, UCA1, HOTAIR, MIAT, NEAT1, LIPCAR, H19, NRF, NRON, MHRT, PVT1, Heat2, CASC7, GAS5, MALAT1, APPAT, HIF1A-AS1, KCNQ1OT1, NEXN in different kinds of CVD and discussed their clinical application potential as biomarker, which can help us better understand the mechanism of CVD.
心血管疾病（CVD），如心肌缺血、心肌梗死、心力衰竭、动脉粥样硬化、高血压、心律失常及其并发症，与发病率和死亡率的增加相关，因此有必要开发新的心血管疾病诊断标志物。长链非编码RNA（lncRNAs）已成为心血管疾病中有良好发展前景的一类新生物标志物。大量研究证实lncRNAs作为不同类型心血管疾病的诊断、预后和预测工具的可行性。在本综述中，我们总结了关于循环lncRNA作为心血管疾病潜在生物标志物的临床应用价值和病理生理机制的现有知识。我们回顾了循环lncRNAs如ZFAS1、CDR1AS、CHAST、UCA1、HOTAIR、MIAT、NEAT1、LIPCAR、H19、NRF、NRON、MHRT、PVT1、Heat2、CASC7、GAS5、MALAT1、APPAT、HIF1A-AS1、KCNQ1OT1、NEXN在不同类型心血管疾病中的应用范围和变化，并讨论了它们作为生物标志物的临床应用潜力，这有助于我们更好地理解心血管疾病的机制。
Zotero 插件